Tech Transfer Roundup: Voyager Brings Home Pair Of CNS Collaborations
Executive Summary
Collaboration with Washington University to co-develop therapies targeting apoliprotein A makes up part of Denali's big August push in Alzheimer's. Kleo gets global rights to two Yale antibody programs and raises Series A cash.
You may also be interested in...
Start-Up Quarterly Statistics, Q3 2016
A review of biopharma start-up dealmaking and financing from July through September 2016, based on data from Strategic Transactions.
Denali Builds Neurodegeneration Pipeline Through Discovery, Collaborations And Lots Of Cash
The amount of venture capital that Denali Therapeutics Inc. has raised and the number of collaborations it's negotiated in less than two years is pretty staggering for a startup biopharmaceutical company, not to mention a startup focused on the central nervous system and neurodegeneration.
Deal Watch: Flagship Ventures Doubles Down On Microbiome
Two of the VC's biotechs merged to create an immuno-microbiome company, while Seres is working with Emulate on better tech for microbiome research. UK specialty pharma Martindale acquired small hospital products-focused UK firm Viridian, and Bayer and X-Chem expanded their drug discovery alliance.